Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Published:2022-05 Issue:5 Volume:23 Page:612-624
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Vano Yann-Alexandre,Elaidi Réza,Bennamoun Mostefa,Chevreau Christine,Borchiellini Delphine,Pannier Diane,Maillet Denis,Gross-Goupil Marine,Tournigand Christophe,Laguerre Brigitte,Barthélémy Philippe,Coquan Elodie,Gravis Gwenaëlle,Houede Nadine,Cancel Mathilde,Huillard Olivier,Beuzeboc Philippe,Fournier Laure,Méjean Arnaud,Cathelineau Xavier,Doumerc Nicolas,Paparel Philippe,Bernhard Jean-Christophe,de la Taille Alexandre,Bensalah Karim,Tricard Thibault,Waeckel Thibaut,Pignot Géraldine,Braychenko Elena,Caruso Stefano,Sun Cheng-Ming,Verkarre Virginie,Lacroix Guillaume,Moreira Marco,Meylan Maxime,Bougouïn Antoine,Phan Letuan,Thibault-Carpentier Christelle,Zucman-Rossi Jessica,Fridman Wolf Herman,Sautès-Fridman Catherine,Oudard Stéphane

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Renal cell carcinoma;Hsieh;Nat Rev Dis Primers,2017

2. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

3. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

4. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021

5. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma;Motzer;N Engl J Med,2021

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma;2024-08-13

2. Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review;Expert Review of Anticancer Therapy;2024-06-03

3. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma;European Journal of Cancer;2024-06

4. High grade adverse event reporting and enrolment in gynecologic oncology clinical trials;Gynecologic Oncology;2024-06

5. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review;International Immunopharmacology;2024-06